• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    2024 Entrepreneurship Summit Presented by the Harvard Undergraduate Venture Capital Group: Agenda and Speakers

    3/22/24 6:14:00 PM ET
    $BEAM
    $DASH
    $LYFT
    $AVEO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    EDP Services
    Technology
    Get the next $BEAM alert in real time by email

    The Harvard Undergraduate Venture Capital Group (VCG) will hold its annual Entrepreneurship Summit on Sunday, March 24, 2024, from 8 AM to 5:30 PM at The Ritz-Carlton in Boston. The Summit is the largest undergraduate entrepreneurship and venture capital conference in the nation and will bring together founders of unicorn startups, CEOs of public companies, and renowned venture capital and private equity investors.

    The event will convene over 55 speakers and 15 panels on Leadership, Investing, and Entrepreneurship with Advanced Tracks discussing topics ranging from biotech to investing in AI.

    Keynote speakers include:

    • Steve Kraus, Partner at Bessemer Venture Partners and world-renowned healthcare investor. He invested in Sirtris Pharmaceuticals (NASDAQ:SIRT); Affymax (NASDAQ:AFFY); Aveo (NASDAQ:AVEO); Alnara, acquired by Eli Lilly; and many more.
    • John Evans, CEO of Beam Therapeutics (NASDAQ:BEAM), leading biotechnology company in gene therapies with a market capitalization of $2.85 billion.
      • Fireside chat with Steve Knight, President and Managing Partner of F-Prime Capital, top VC firm in healthcare and technology with $2+ billion AUM.
    • Tim Westergren, Founder and Former CEO of Pandora (NYSE:P), the music streaming service with a market capitalization of over $100 billion. He most recently founded HelloCreator, an AI-based application to help creators navigate their careers.
    • Earl Jones, Partner at DCVC, deep tech VC firm with over $2.6 billion AUM, and Alex Rappaport, Founder and CEO of ZwitterCo, a company that develops membranes that reuses the world's toughest wastewaters.

    Advanced Track session speakers feature:

    • Nick Sinai, Senior Advisor at Insight Partners, former White House U.S. Deputy Chief Technology Officer, and former presidential cabinet member under Obama.
    • James Currier, Founder of NFX, a $1.6B venture capital firm focused on network effect businesses. He invested in Doordash (NASDAQ:DASH), Lyft (NASDAQ:LYFT), Poshmark (MCAP: $1.42B), and more.
    • Bryce Youngren, Managing Partner at Polaris Growth Fund, a dedicated growth buyout firm with over $5.5 billion in assets under management.

    "For this year's Entrepreneurship Summit, we are excited to build off of the momentum of last year's leadership and take it to new heights. We're looking forward to gathering the next generation of entrepreneurs under one roof for a full day of community building," said Nick Apostolicas, President of VCG.

    VCG gratefully acknowledges everyone who made this extraordinary event possible. Special thanks to our PLATINUM SPONSOR, DCVC; our GOLD SPONSOR, Graphene Ventures; our SILVER SPONSORS, F-Prime Capital, Third Rock Ventures, Lemann Program on Creativity and Entrepreneurship (LPCE), and Forum Ventures; and our BRONZE SPONSORS, Insight Partners, Blumberg Capital, Clearvision Ventures, Xfund, Octonic VR, senhasegura, WakeCap Technologies, and Boston College High School Jack Shields Center for Innovation.

    To purchase summit tickets, visit harvardvcg2024entrepreneurshipsummit.eventbrite.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240322999918/en/

    Get the next $BEAM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BEAM
    $DASH
    $LYFT
    $AVEO

    CompanyDatePrice TargetRatingAnalyst
    Beam Therapeutics Inc.
    $BEAM
    2/20/2026$74.00Buy
    Canaccord Genuity
    DoorDash Inc.
    $DASH
    1/14/2026$280.00Outperform
    BNP Paribas Exane
    Lyft Inc.
    $LYFT
    12/19/2025$16.00Neutral → Underperform
    Wedbush
    Lyft Inc.
    $LYFT
    12/3/2025$20.00Sell → Neutral
    Arete
    DoorDash Inc.
    $DASH
    11/19/2025$260.00Hold → Buy
    Jefferies
    DoorDash Inc.
    $DASH
    11/13/2025$260.00Neutral → Outperform
    Wedbush
    DoorDash Inc.
    $DASH
    10/27/2025$315.00Buy
    Goldman
    DoorDash Inc.
    $DASH
    10/24/2025$272.00Equal Weight
    Barclays
    More analyst ratings

    $BEAM
    $DASH
    $LYFT
    $AVEO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Llewellyn Lindsay Catherine covered exercise/tax liability with 51,677 shares, decreasing direct ownership by 7% to 720,511 units (SEC Form 4)

    4 - Lyft, Inc. (0001759509) (Issuer)

    2/24/26 6:24:19 PM ET
    $LYFT
    Real Estate

    CHIEF ACCOUNTING OFFICER Hope Stephen W. covered exercise/tax liability with 6,055 shares, decreasing direct ownership by 2% to 305,854 units (SEC Form 4)

    4 - Lyft, Inc. (0001759509) (Issuer)

    2/24/26 6:22:10 PM ET
    $LYFT
    Real Estate

    CHIEF FINANCIAL OFFICER Brewer Erin covered exercise/tax liability with 88,880 shares, gifted 76,190 shares and received a gift of 76,190 shares, decreasing direct ownership by 14% to 1,014,851 units (SEC Form 4)

    4 - Lyft, Inc. (0001759509) (Issuer)

    2/24/26 6:20:19 PM ET
    $LYFT
    Real Estate

    $BEAM
    $DASH
    $LYFT
    $AVEO
    SEC Filings

    View All

    SEC Form S-8 filed by Beam Therapeutics Inc.

    S-8 - Beam Therapeutics Inc. (0001745999) (Filer)

    2/24/26 7:22:37 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Beam Therapeutics Inc.

    10-K - Beam Therapeutics Inc. (0001745999) (Filer)

    2/24/26 7:10:57 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Beam Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Beam Therapeutics Inc. (0001745999) (Filer)

    2/24/26 7:05:46 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BEAM
    $DASH
    $LYFT
    $AVEO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DoorDash to Wind Down Deliveroo and Wolt Operations in Four Countries

    Exiting Qatar, Singapore, Japan, and Uzbekistan; actions not expected to materially impact DoorDash's financial outlook DoorDash, Inc. (NASDAQ:DASH) today announced it is exiting four countries across its Deliveroo and Wolt brands: Qatar, Singapore, Japan, and Uzbekistan. The company will begin an orderly wind-down process in each country and will work closely with local teams and partners to support employees, merchants, consumers, riders, and couriers through the transition. These decisions follow a multi-month review of country-specific conditions and reflect DoorDash's continued focus on investing where it sees the clearest path to sustainable scale and long-term leadership. DoorDas

    2/25/26 1:15:00 AM ET
    $DASH
    EDP Services
    Technology

    Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

    New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 Updated Phase 1/2 Data and Next Steps for Pivotal Development for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) on Track for Q1 2026 Strategic Financing Agreement with Sixth Street Provides up to $500 Million in Long-term, Non-dilutive Capital to Fund Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD); U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026 Expected Cash Runway Now into Mid-2029 Through Execution of Key Clinical, Regulatory and Commercial Milestones Beam to Host

    2/24/26 7:01:00 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street

    $100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD) CAMBRIGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM) today announced that it has entered into a strategic financing agreement with Sixth Street for substantial, long-term, non-dilutive capital to fund the potential launch of ristoglogene autogetemcel (risto-cel) in sickle cell disease (SCD). The $500 million senior secured credit facility includes $100 million funded at close; up to $300 million availab

    2/24/26 7:00:00 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BEAM
    $DASH
    $LYFT
    $AVEO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Risher John David bought $100,179 worth of shares (7,490 units at $13.38), increasing direct ownership by 0.07% to 11,481,792 units (SEC Form 4)

    4 - Lyft, Inc. (0001759509) (Issuer)

    2/18/26 4:10:21 PM ET
    $LYFT
    Real Estate

    Chief Executive Officer Risher John David bought $99,617 worth of shares (5,030 units at $19.80), increasing direct ownership by 0.04% to 11,802,296 units (SEC Form 4)

    4 - Lyft, Inc. (0001759509) (Issuer)

    12/11/25 8:53:23 PM ET
    $LYFT
    Real Estate

    Director Lin Alfred bought $100,277,150 worth of shares (514,047 units at $195.07) (SEC Form 4)

    4 - DoorDash, Inc. (0001792789) (Issuer)

    11/28/25 7:02:02 PM ET
    $DASH
    EDP Services
    Technology

    $BEAM
    $DASH
    $LYFT
    $AVEO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Beam Therapeutics with a new price target

    Canaccord Genuity initiated coverage of Beam Therapeutics with a rating of Buy and set a new price target of $74.00

    2/20/26 8:23:45 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BNP Paribas Exane initiated coverage on DoorDash with a new price target

    BNP Paribas Exane initiated coverage of DoorDash with a rating of Outperform and set a new price target of $280.00

    1/14/26 8:40:46 AM ET
    $DASH
    EDP Services
    Technology

    Lyft downgraded by Wedbush with a new price target

    Wedbush downgraded Lyft from Neutral to Underperform and set a new price target of $16.00

    12/19/25 8:45:08 AM ET
    $LYFT
    Real Estate

    $BEAM
    $DASH
    $LYFT
    $AVEO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for FOTIVDA issued to AVEO PHARMACEUTICALS INC

    Submission status for AVEO PHARMACEUTICALS INC's drug FOTIVDA (ORIG-1) with active ingredient TIVOZANIB HYDROCHLORIDE has changed to 'Approval' on 03/10/2021. Application Category: NDA, Application Number: 212904, Application Classification: Type 1 - New Molecular Entity

    3/29/21 5:44:34 PM ET
    $AVEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FOTIVDA

    Submission status for AVEO PHARMACEUTICALS INC's drug FOTIVDA (ORIG-1) with active ingredient TIVOZANIB has changed to 'Approval' on 03/10/2021. Application Category: NDA, Application Number: 212904, Application Classification: Type 1 - New Molecular Entity

    3/10/21 2:49:22 PM ET
    $AVEO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BEAM
    $DASH
    $LYFT
    $AVEO
    Leadership Updates

    Live Leadership Updates

    View All

    Milan Kovac Joins DoorDash Board of Directors

    DoorDash, Inc. (NASDAQ:DASH) announced today that Milan Kovac, former Vice President of Optimus Robotics and Autopilot at Tesla, has been appointed to the company's Board of Directors, effective January 16, 2026. Tony Xu, co-founder and CEO of DoorDash, Inc., said, "Milan has spent his career building and scaling ambitious engineering programs at the intersection of AI, autonomy, and robotics. He brings a rare combination of technical depth and operational leadership. That experience will be invaluable as we continue to build products and infrastructure that help local businesses grow, give consumers access to more of their communities, and create new ways for people to earn. I'm excited

    1/20/26 4:05:00 PM ET
    $DASH
    EDP Services
    Technology

    TKO and DoorDash Announce Official Partnership Across WWE® and UFC®

    DoorDash Named Official On-Demand Delivery Partner of WWE and UFC DoorDash to Deliver First-of-its-Kind Integrations and Fan Engagement Opportunities with WWE Superstars and UFC Athletes TKO Group Holdings, Inc. (NYSE:TKO) and DoorDash (NASDAQ:DASH) today announced an official partnership that will connect fans to custom integrations and experiences across WWE, the global leader in sports entertainment, and UFC, the world's premier mixed martial arts organization. DoorDash will have a prominent presence across WWE's and UFC's most high-profile moments and platforms, including live events and broadcasts, and will also leverage the massive presence WWE has across social media and digita

    11/20/25 8:00:00 AM ET
    $DASH
    $TKO
    EDP Services
    Technology
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    DoorDash and Serve Robotics Partner to Bring Serve's Delivery Robots to the DoorDash Platform

    SAN FRANCISCO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- DoorDash (NASDAQ:DASH), a leading local commerce platform globally, and Serve Robotics Inc. (NASDAQ:SERV), a leading autonomous sidewalk delivery company, today announced a new multi-year strategic partnership to roll out autonomous robot deliveries across the U.S. Los Angeles residents ordering through the DoorDash app from participating merchants may have their order delivered by a Serve robot. The partnership will expand the potential volume of orders available to Serve for delivery. This partnership reflects DoorDash's broader multi-modal delivery platform strategy, which integrates Dashers, drones, and autonomous robots to meet incr

    10/9/25 7:30:00 AM ET
    $DASH
    $SERV
    EDP Services
    Technology
    Industrial Specialties
    Consumer Discretionary

    $BEAM
    $DASH
    $LYFT
    $AVEO
    Financials

    Live finance-specific insights

    View All

    Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

    New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 Updated Phase 1/2 Data and Next Steps for Pivotal Development for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) on Track for Q1 2026 Strategic Financing Agreement with Sixth Street Provides up to $500 Million in Long-term, Non-dilutive Capital to Fund Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD); U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026 Expected Cash Runway Now into Mid-2029 Through Execution of Key Clinical, Regulatory and Commercial Milestones Beam to Host

    2/24/26 7:01:00 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    DoorDash Releases Fourth Quarter and Full Year 2025 Financial Results

    DoorDash, Inc. (NASDAQ:DASH) today announced its financial results for the quarter and fiscal year ended December 31, 2025. In addition to our financial results below, our annual letter to shareholders is available on the DoorDash investor relations website at http://ir.doordash.com. In 2025, we accelerated growth in our U.S. restaurant category, expanded consumer affordability through record DashPass signups, increased consumer retention and order frequency in our grocery and retail categories by improving selection and quality, increased merchant value by launching new services such as reservations for restaurants and Smart Campaigns for ads, and drove strong organic growth internationa

    2/18/26 4:05:00 PM ET
    $DASH
    EDP Services
    Technology

    Lyft To Announce Fourth Quarter and Full-Year 2025 Financial Results

    Lyft, Inc. (NASDAQ:LYFT) (the "Company" or "Lyft") will release financial results for the fourth quarter and full-year 2025 after the close of the market on Tuesday, February 10, 2026. On the same day, Lyft will host a conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss these financial results and business highlights. To listen to the live audio webcast, please visit the Company's Investor Relations page at https://investor.lyft.com. The archived webcast will be available on the Company's Investor Relations page shortly after the call. Lyft announces material information to the public about the Company, its products and services and other matters through a va

    1/20/26 4:05:00 PM ET
    $LYFT
    Real Estate

    $BEAM
    $DASH
    $LYFT
    $AVEO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Lyft Inc.

    SC 13G/A - Lyft, Inc. (0001759509) (Subject)

    12/4/24 2:38:58 PM ET
    $LYFT
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Lyft Inc.

    SC 13G/A - Lyft, Inc. (0001759509) (Subject)

    11/12/24 10:32:11 AM ET
    $LYFT
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

    SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

    11/12/24 9:50:15 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care